133 related articles for article (PubMed ID: 35024377)
1. A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.
Chaurasiya S; Yang A; Zhang Z; Lu J; Valencia H; Kim SI; Woo Y; Warner SG; Olafsen T; Zhao Y; Wu X; Fein S; Cheng L; Cheng M; Ede N; Fong Y
Mol Ther Methods Clin Dev; 2022 Mar; 24():102-116. PubMed ID: 35024377
[TBL] [Abstract][Full Text] [Related]
2. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer.
Woo Y; Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Von Hoff D; Fong Y
J Am Coll Surg; 2020 Apr; 230(4):709-717. PubMed ID: 32032721
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
4. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
[TBL] [Abstract][Full Text] [Related]
5. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.
Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Yuan YC; Liu Z; Han H; Von Hoff D; Fong Y; Woo Y
Cancer Gene Ther; 2022 Jun; 29(6):722-733. PubMed ID: 34108669
[TBL] [Abstract][Full Text] [Related]
6. Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Valencia H; Fong Y; Woo Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762490
[TBL] [Abstract][Full Text] [Related]
7. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Olafsen T; Warner SG; Fong Y; Woo Y
Mol Ther Oncolytics; 2022 Mar; 24():331-339. PubMed ID: 35118191
[TBL] [Abstract][Full Text] [Related]
8. A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression.
Warner SG; Kim SI; Chaurasiya S; O'Leary MP; Lu J; Sivanandam V; Woo Y; Chen NG; Fong Y
Mol Ther Oncolytics; 2019 Jun; 13():82-92. PubMed ID: 31061881
[TBL] [Abstract][Full Text] [Related]
9. CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.
Yuan Y; Egelston C; Colunga Flores O; Chaurasiya S; Lin D; Chang H; Chong LMO; Seiz A; Shah M; Meisen WH; Tang A; Martinez N; Pickett W; Murga M; Yost SE; Stewart D; Zhang J; Ede N; Modi B; Kessler J; Rand J; Fong Y
Ther Adv Med Oncol; 2023; 15():17588359231210675. PubMed ID: 38028143
[TBL] [Abstract][Full Text] [Related]
10. An oncolytic poxvirus encoding hNIS, shows anti-tumor efficacy and allows tumor imaging in a liver cancer model.
Chaurasiya S; Valencia H; Zhang Z; Kim SI; Yang A; Lu J; Woo Y; Warner SG; Ede NJ; Fong Y
Mol Cancer Ther; 2023 May; 22(7):882-90. PubMed ID: 37196156
[TBL] [Abstract][Full Text] [Related]
11. An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model.
Chaurasiya S; Valencia H; Zhang Z; Kim SI; Yang A; Lu J; Woo Y; Warner SG; Ede NJ; Fong Y
Mol Cancer Ther; 2023 Jun; ():OF1-OF9. PubMed ID: 37294888
[TBL] [Abstract][Full Text] [Related]
12. A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models.
Chaurasiya S; Chen NG; Lu J; Martin N; Shen Y; Kim SI; Warner SG; Woo Y; Fong Y
Cancer Gene Ther; 2020 Apr; 27(3-4):125-135. PubMed ID: 31209267
[TBL] [Abstract][Full Text] [Related]
13. Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer.
Choi AH; O'Leary MP; Lu J; Kim SI; Fong Y; Chen NG
Mol Ther Oncolytics; 2018 Jun; 9():22-29. PubMed ID: 29988465
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.
Wang J; Arulanandam R; Wassenaar R; Falls T; Petryk J; Paget J; Garson K; Cemeus C; Vanderhyden BC; Wells RG; Bell JC; Le Boeuf F
J Nucl Med; 2017 Feb; 58(2):221-227. PubMed ID: 27635026
[TBL] [Abstract][Full Text] [Related]
15. A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection.
O'Leary MP; Warner SG; Kim SI; Chaurasiya S; Lu J; Choi AH; Park AK; Woo Y; Fong Y; Chen NG
Mol Ther Oncolytics; 2018 Jun; 9():13-21. PubMed ID: 29988502
[TBL] [Abstract][Full Text] [Related]
16. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus.
Haddad D; Chen NG; Zhang Q; Chen CH; Yu YA; Gonzalez L; Carpenter SG; Carson J; Au J; Mittra A; Gonen M; Zanzonico PB; Fong Y; Szalay AA
J Transl Med; 2011 Mar; 9():36. PubMed ID: 21453532
[TBL] [Abstract][Full Text] [Related]
17. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter.
Gholami S; Haddad D; Chen CH; Chen NG; Zhang Q; Zanzonico PB; Szalay AA; Fong Y
Surgery; 2011 Dec; 150(6):1040-7. PubMed ID: 22136819
[TBL] [Abstract][Full Text] [Related]
18. Development of a dual membrane protein reporter system using sodium iodide symporter and mutant dopamine D2 receptor transgenes.
Hwang DW; Kang JH; Chang YS; Jeong JM; Chung JK; Lee MC; Kim S; Lee DS
J Nucl Med; 2007 Apr; 48(4):588-95. PubMed ID: 17401096
[TBL] [Abstract][Full Text] [Related]
19. Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter.
Peerlinck I; Merron A; Baril P; Conchon S; Martin-Duque P; Hindorf C; Burnet J; Quintanilla M; Hingorani M; Iggo R; Lemoine NR; Harrington K; Vassaux G
Clin Cancer Res; 2009 Nov; 15(21):6595-601. PubMed ID: 19861465
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
